On February 25, 2025, NGL Fine-Chem, a pharmaceutical company, and its promoters reached a settlement with the capital market regulator, the Securities and Exchange Board of India (SEBI) regarding alleged violations of shareholding disclosure requirements. Both, the company and the promoters have agreed to pay a total of ₹92.21 lakh to resolve the issue. The …